Nasal Spray of Neutralizing Monoclonal Antibody 35B5 Confers Potential Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern (VOCs): A Small-scale Clinical Trial.

Lilin YeShuai YueYang YangSen YangZhiwei PanXiaofan YangLeiqiong GaoJing ZhouZhirong LiLi HuJianfang TangQing WuShun LeiQin TianYifei WangYaxing HaoLifan XuQizhao HuangBo ZhuYaokai ChenXiangyu ChenLilin Ye

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

A single nasal spray of 35B5 formation conveys 24-hour effective protection against SARS-CoV-2 VOCs, including the Alpha, Beta, Delta, or Omicron variants. Thus, 35B5 nasal spray might be potential in strengthening SARS-CoV-2 prevention, especially in the high-risk population.

Keyphrases

sars cov
respiratory syndrome coronavirus
monoclonal antibody
clinical trial
chronic rhinosinusitis
copy number
blood pressure
study protocol
dna methylation
dengue virus
genome wide
zika virus